Seaport Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SPTX | GHRS | ATAI | ANRO | MPLT | GPCR | |
|---|---|---|---|---|---|---|
| Market cap | 1.12B | 1.37B | — | 914.34M | 372.91M | 1.45B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -8.4 | -10.8 | — | -7.3 | -2.0 | -9.6 |
| Price/book | 2.8 | 3.8 | — | 3.7 | 0.9 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +1.81% | +49.23% | — | +101.06% | −57.44% | −36.82% |
| Today | +3.76% | −1.73% | 0.00% | +2.64% | −1.47% | +0.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SPTX news ›Seaboard GAAP EPS of $29.23, revenue of $2.77B
Seaboard press release (SEB): Q3 GAAP EPS of $29.23. Revenue of $2.77B (+9.1% Y/Y). - Seaboard press release (SEB): Q3 GAAP EPS of $29.23.
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Announced positive topline data from Phase 1 driving simulation trial of GlyphAllo™, showing that GlyphAllo did not impair next-morning driving performance compared to placebo Dosed first patient in Phase 2a trial of GlyphAgo™ in patients…
Seaport Therapeutics, Inc. GAAP EPS of -$0.49 beats by $0.09
Seaport Therapeutics reports Q3 GAAP EPS of -$0.49, beating estimates by $0.09. - Seaport Therapeutics, Inc. press release (SPTX): Q3 GAAP EPS of -$0.49 beats by $0.09. More on Seaport Therapeutics, Inc.
Seaport Therapeutics: Borrowed Efficacy, Engineered Safety, And A Post-IPO Discount
Seaport Therapeutics offers CNS upside with Glyph technology, solid cash runway, and key Phase 2b data ahead. Read more on SPTX stock here. - Seaport Therapeutics leverages proprietary Glyph technology to enhance bioavailability and safety…
Seaport Therapeutics, Inc.'s (NASDAQ:SPTX) Lock-Up Period Will End on October 28th
View Our Latest Analysis on SPTX Shares of SPTX stock opened at $19.28 on Wednesday. Seaport Therapeutics has a 12-month low of $14.85 and a 12-month high of $28.38. The stock's fifty day moving average is $21.74. Seaport Therapeutics…
NextCure: JP Sailing Capital reports 9.9% stake
Two filers report the same passive stake in NextCure (NXTC), with shared voting power. Stock Titan - [SCHEDULE 13G] NextCure, Inc. Passive Investment Disclosure (>5%) NextCure: JP Sailing Capital reports 9.9% stake JP Sailing Fund directly…
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 3.6% - Here's Why
Seaport Therapeutics, Inc. (NASDAQ:SPTX - Get Free Report)'s stock price shot up 3.6% during trading on Wednesday. The company traded as high as $16.79 and last traded at $16.66. 42,924 shares traded hands during trading, a decline of 81%…
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to The National Law Review Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference…
Weekly Investment Analysts’ Ratings Changes for Seaport Therapeutics (SPTX)
Posted by Mitch Edgeman on Oct 12th, 2026 Seaport Therapeutics (NASDAQ: SPTX) recently received a number of ratings updates from brokerages and research firms: Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on…
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Seaport has initiated a Phase 2a clinical trial evaluating GlyphAgo in adults with generalized anxiety disorder and sleep disturbance, with topline results expected in early 2028. Seaport also plans to initiate a Phase 2/3 clinical trial…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com3
- marketbeat.com2
- natlawreview.com2
- stocktitan.net1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.